A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism

Inclusion Criteria: 1. Aged 18-75 years（Include the critical value）AND 2. High-risk PE or medium high-risk PE AND 3. PE symptom duration ≤14 days AND 4. PLT≥100×10\^9/L，ALT and AST≤2.5ULN，TBIL\<ULN，Cr within the normal range AND 5. Informed consent can be obtained from subject or Legally Authorized Representative Exclusion Criteria: 1. Hemorrhagic or unexplained stroke history 2. Ischemic stroke or transient ischemic attack (TIA) within 6 months 3. The existence of the central nervous system injury or tumor 4. Severe trauma，major surgery or head injury within 3 weeks 5. Active bleeding within 1 month 6. Clinician deems high-risk for bleeding 7. Using anticoagulants (after a washout period can be randomized) 8. Pregnancy or delivery within 1 week 9. Vascular puncture which can not be oppressed 10. Cardiopulmonary resuscitation within 10 days 11. Systolic blood pressure above 180 mmHg or diastolic blood pressure above 100mmHg 12. Severe liver dysfunction 13. Infective endocarditis 14. Arterial aneurysm or arteriovenous malformation or suspected aortic dissection 15. left atrial thrombus 16. Neurosurgery or eye surgery within 1 month 17. Hemorrhagic diabetic retinopathy 18. Serious cardiac insufficiency 19. ventricular arrhythmias 20. Known allergic to prourokinase，urokinase，recombinant tissue-type plasminogen activator，contrast agent or any drug in the trial 21. Do not allow for 30 days' study 22. Any disease or condition is not suitable for intravenous thrombolysis 23. Lactating women or plan to pregnant women during the trial，or don't want to during the study period using effective contraception or abstinence of male and female patients with possibility of fertility 24. Clinician thinks patient doesn't fit to participate in the test of other diseases or conditions